Pure Global AI
NCT06416969Not yet recruiting

Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation

Stimulation of Regional Lipolysis and Adipocyte Lipolysis Proteins
Mayo ClinicPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Obesity
Drug/Device/Intervention
Somatostatin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mayo Clinic
Location
Rochester, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
May 01, 2024
End date
Apr 01, 2027
Enrollment
24 participants
Primary outcome

Free Fatty Acid (FFA) release from femoral, splanchnic and upper body subcutaneous adipose tissue

Summary

Adults who gain most of their excess weight in the abdominal area typically do not respond to
 factors that turn on fat cells the same way as people who don't have excessive weight.
 Researchers are trying to understand why fat tissue responds differently in people with
 different body types.

ICD-10 classifications
ObesityOther obesityObesity, unspecifiedObesity due to excess caloriesObesity and other hyperalimentation
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06416969
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06416969 through Pure Global AI's free database. This Phase 1 trial is sponsored by Mayo Clinic and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.